[Skip to Content]
[Skip to Content Landing]
Citations 0
Poster Presentations: American Head and Neck Society
August 2006

P104 Radioimmunotherapy of Head and Neck Cancer Xenografts Using 131I-L19-SIP for Selective Targeting of Tumor Vasculature

Arch Otolaryngol Head Neck Surg. 2006;132(8):886. doi:10.1001/archotol.132.8.886-a

VU University Medical Center, Amsterdam, the Netherlands;

Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich;

Research Laboratories of Schering AG, Berlin, Germany;

Istituto G. Gaslini, Genova, Italy

Objective: The human monoclonal antibody L19-SIP is directed against the extra domain B of fibronectin (ED-B), a marker of tumor angiogenesis. The potential of radioimmunotherapy (RIT) with L19-SIP was evaluated, either alone or in combination with the anti–epidermal growth factor receptor (EGFR) antibody cetuximab, for treatment of head and neck squamous cell carcinoma (HNSCC).

×